-
Mashup Score: 1ASCO - 3 year(s) ago
The ASCO EDI Action Plan describes specific initiatives ASCO plans to continue, expand, or initiate, and outlines targets for the organization to reach over the next three to five years. ASCO aims to address the wide variety of factors—including race/ethnicity, age, gender, sexual orientation, and geography—that can impact access to cancer care and outcomes,…
Source: m.email.asco.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5ASCO - 4 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @stolaney1: Sorry, wrong link in this Link on ASCO: https://t.co/immXuek7sm
-
-
Mashup Score: 4ASCO - 4 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @stolaney1: Sorry, wrong link in this Link on ASCO: https://t.co/immXuek7sm
-
-
Mashup Score: 2ASCO - 4 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @stolaney1: Sorry, wrong link in this Link on ASCO: https://t.co/immXuek7sm
-
-
Mashup Score: 7ASCO - 4 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Latest Headlines, Oncologists1Tweet-
FDA approves abemaciclib with endocrine therapy for or adjuvant treatment of patients with HR positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20% #bcsm @MayoCancerCare https://t.co/tqzhLAZgOa
-
-
Mashup Score: 9ASCO - 4 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DocCatenacci: !!FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer!!: https://t.co/SxrF1wzqEr
-
-
Mashup Score: 0ASCO - 5 year(s) ago
Submitting expanded access requests to FDA just got easier for physicians. The Reagan-Udall Foundation for the FDA, with input from experts at FDA, today launched Expanded Access eRequest to streamline expanded access for individual patients in non-emergency settings. “Time is critical when patients have a serious or life-threatening disease or condition and…
Source: m.email.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Submitting expanded access requests to FDA just got easier for physicians. Details from the Clinical Affairs Department from @ASCO here: https://t.co/3dumGyylif
-
-
Mashup Score: 7ASCO - 5 year(s) ago
Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001, NCT03157128) in patients whose tumors had RET alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, polymerase chain reaction, or fluorescence in situ hybridization. The…
Source: m.email.asco.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @VivekSubbiah: RET inhibitor is @US_FDA @FDAOncology Approved in RET + #lungcancer #thyroidcancer https://t.co/ecu94I2MAX Huge win for p…
-
-
Mashup Score: 9ASCO - 5 year(s) ago
Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001, NCT03157128) in patients whose tumors had RET alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, polymerase chain reaction, or fluorescence in situ hybridization. The…
Source: m.email.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RET inhibitor is @US_FDA @FDAOncology Approved in RET + #lungcancer #thyroidcancer https://t.co/ecu94I2MAX Huge win for patients with RET altered #cancers #LCSM #thycsm. Read👉 RET review published in @ASCO_pubs @ASCO https://t.co/zeLLZmfI3l https://t.co/8tnqRhi7bv
-
-
Mashup Score: 2ASCO - 5 year(s) ago
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner….
Source: m.email.asco.orgCategories: Hem/OncsTweet-
Food and Drug Administration @FDAOncology approved mitomycin for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). https://t.co/QYEpgCttYN
-
ASCO announces new equity, diversity, inclusion plan https://t.co/uQv0fEH3bm